Alkem MedTech, a wholly-owned medical devices subsidiary of Alkem, today announced the execution of a binding offer for acquiring a majority stake in Occlutech Holding AG (Occlutech), a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants.

Alkem MedTech intends to buy up to 55% stake in Occlutech for a consideration of €99.4 million (Approx. Rs. 1,074 crore), subject to statutory approvals. This acquisition represents a significant step in Alkem MedTech’s journey to build a global footprint and enables its entry into advanced cardiovascular devices.

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure. Occlutech is the second-largest company in Europe in the minimally invasive cardiac implants segment and the third-largest globally. It operates manufacturing and R&D facilities in Germany and Turkey, a global distribution hub in Sweden, and clinical operations in the US.

In calendar year 2025, Occlutech recorded a revenue of €49.4 million (unaudited), representing a 15.7% CAGR over the past three years. Occlutech derives about 85% of its revenue from Europe and the US.

Commenting on this development, B. N. Singh, Executive Chairman, Alkem Laboratories said, “The acquisition of Occlutech opens up significant opportunities for Alkem MedTech, and reinforces Alkem’s long-term vision of becoming a global player in the medical devices industry, replicating its success story in pharma. For Alkem, this step reinforces our broader vision of building strong, sustainable and future-ready businesses with advanced, trusted healthcare solutions that improve patient care.”

Kaustav Banerjee, Chief Executive Officer, Alkem MedTech said, “Occlutech has established capabilities in structural heart devices, a highly-experienced management team, world class R&D and manufacturing facilities, and strong quality and regulatory framework, which provides a strong foundation for Alkem MedTech to begin its journey in the cardiology segment and support sustainable growth. It gives us entry into high-barrier, high-value markets such as the US, Japan, Germany and other western European markets.”

Tor Peters, Chief Executive Officer, Occlutech, said, “Over the last 23 years, we have built a company driven by patient centricity and innovation. With Alkem MedTech as our strategic investor, we aim to make an impact together through continuous R&D and innovation programmes, bringing high-quality products to serve unmet needs and tap new markets. We also expect cost optimisation synergies that will create value for both organisations. We are confident that Alkem’s capabilities and strong foundation in healthcare will support the next growth phase of our journey.”

The Boston Consulting Group (BCG) acted as an advisor in this transaction.